Drugs / Triazavirin
Triazavirin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04581915 | Sep 2020 → Apr 2021 | COVID-19 | Wits Health Consortium (Pty) Ltd | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04973462 Comparator | Aug → Sep 2021 | COVID-19 | Ain Shams University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triazavirin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04973462 ↗ |
| Known as | Riamilovir | “Triazavirin (Riamilovir)” NCT04581915 ↗ |
| Known as | TZV | “Triazavirin (TZV), a new antiviral drug, has been on the market in Russia since 2015.” NCT04973462 ↗1“Triazavirin (TZV)” NCT04581915 ↗ |
| Action | Inhibit | “The principle mode of action of TZV is inhibiting the synthesis of viral RNA and preventing the replication of genomic fragments.” NCT04973462 ↗ |
| Modality | Small molecule | “It is a synthetic compound analogue to the purine nucleoside bases.” NCT04973462 ↗ |
| Route | Oral | “taken orally three times per day” NCT04581915 ↗ |